Company logo

BCRX - BioCryst Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
Durham, United States
Type: Equity

BCRX price evolution
BCRX
(in millions $) 31 Dec 2023 30 Oct 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $112.45 $152.49 $147.79 $156.6
Short term investments $278.34 $246.69 $264.45 $243.02
Net receivables $56.95 $53.65 $57.67 $48.64
Inventory $28.68 $29.63 $27.03 $27.47
Total current assets $495.97 $502.47 $511.06 $490.88
Long term investments $3.44 $3.43
Property, plant & equipment $7.91 $9 $8.44 $8.38
Goodwill & intangible assets
Total noncurrent assets $20.99 $20.46 $18.83 $18.85
Total investments $278.34 $246.69 $267.9 $246.45
Total assets $516.96 $522.92 $529.88 $509.74
Current liabilities
Accounts payable $20.89 $10.57 $13.89 $6.25
Deferred revenue $0.52 $1.78 $1.2
Short long term debt $26.21 $2.28 $2.53 $2.49
Total current liabilities $149.99 $90.76 $93.5 $85.16
Long term debt $822.5 $843.15 $825.1 $752.87
Total noncurrent liabilities $822.5 $843.15 $825.1 $752.87
Total debt $848.71 $845.43 $827.63 $755.36
Total liabilities $972.49 $933.91 $918.6 $838.02
Shareholders' equity
Retained earnings -$1681.16 -$1619.43 -$1583.28 -$1507.95
Other shareholder equity $1.34 $0.8 $0.69 $0.58
Total shareholder equity -$455.53 -$410.99 -$388.71 -$328.29
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $112.45 $306.24 $507.73 $274.35
Short term investments $278.34 $119.54 $3.21 $28.24
Net receivables $56.95 $50.6 $29.41 $8.65
Inventory $28.68 $27.53 $15.79 $7.04
Total current assets $495.97 $516.5 $566.14 $323.8
Long term investments $18.08 $6.83
Property, plant & equipment $7.91 $15.42 $8.71 $7.11
Goodwill & intangible assets
Total noncurrent assets $20.99 $33.5 $22.02 $10.91
Total investments $278.34 $137.62 $10.04 $28.24
Total assets $516.96 $550 $588.15 $334.71
Current liabilities
Accounts payable $20.89 $14.36 $27.81 $18.71
Deferred revenue $1.22 $1.42 $0.15
Short long term debt $26.21 $2.37 $1.82 $31.18
Total current liabilities $149.99 $105.51 $103.72 $105.65
Long term debt $822.5 $733.28 $591.42 $248.32
Total noncurrent liabilities $822.5 $739.08 $591.42 $248.32
Total debt $848.71 $741.45 $593.24 $279.5
Total liabilities $972.49 $844.6 $695.14 $353.98
Shareholders' equity
Retained earnings -$1681.16 -$1454.62 -$1207.5 -$1023.44
Other shareholder equity $1.34 $0.03 $0.18 $0
Total shareholder equity -$455.53 -$294.6 -$106.99 -$19.26
(in millions $) 31 Dec 2023 30 Oct 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $93.4 $86.74 $82.49 $68.78
Cost of revenue $1.64 $0.95 $0.94
Gross Profit $91.76 $85.61 $81.54 $67.84
Operating activities
Research & development $70.05 $51.25 $48.39
Selling, general & administrative $64.38 $51 $47.87
Total operating expenses $134.43 $97.53 $102.24 $96.25
Operating income -$42.67 -$20.7 -$28.41
Income from continuing operations
EBIT -$38.58 -$45.67 -$25.27
Income tax expense -$1.43 $0.33 $0.74 $0.67
Interest expense $24.58 -$23.9 $28.91 $27.4
Net income
Net income -$61.73 -$36.15 -$75.33 -$53.33
Income (for common shares) -$61.73 -$75.33 -$53.33
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $331.41 $270.83 $157.17 $17.81
Cost of revenue $4.66 $6.59 $7.26 $1.68
Gross Profit $326.75 $264.23 $149.91 $16.14
Operating activities
Research & development $216.57 $253.3 $208.81 $122.96
Selling, general & administrative $213.89 $159.37 $118.82 $67.93
Total operating expenses $430.46 $412.67 $327.63 $190.89
Operating income -$103.71 -$148.44 -$177.72 -$174.76
Income from continuing operations
EBIT -$117.99 -$145.29 -$122.52 -$168.31
Income tax expense $0.31 $2.73 $2.25
Interest expense $108.24 $99.09 $59.29 $14.5
Net income
Net income -$226.54 -$247.12 -$184.06 -$182.81
Income (for common shares) -$226.54 -$247.12 -$184.06 -$182.81
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$61.73 -$36.15 -$75.33 -$53.33
Operating activities
Depreciation $0.42 $0.42 $0.41 $0.41
Business acquisitions & disposals
Stock-based compensation $16.49 $12.28 $12.84 $14.01
Total cash flows from operations -$8.92 -$19.9 -$18.81 -$47.51
Investing activities
Capital expenditures -$0.55 -$0.99 -$0.47 -$0.16
Investments -$27.92 $24.11 -$18.57 -$106.95
Total cash flows from investing -$28.47 $23.12 -$19.04 -$107.11
Financing activities
Dividends paid
Sale and purchase of stock $0.16 $1.49 $1.95 $5.08
Net borrowings -$1.17 -$0.26 $27.4
Total cash flows from financing -$3.17 $1.23 $29.36 $5.08
Effect of exchange rate $0.52 $0.25 -$0.32 -$0.1
Change in cash and equivalents -$40.04 $4.7 -$8.81 -$149.64
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$226.54 -$247.12 -$184.06 -$182.81
Operating activities
Depreciation $1.66 $1.44 $0.78 $0.75
Business acquisitions & disposals
Stock-based compensation $55.62 $44.7 $34.64 $14.79
Total cash flows from operations -$95.14 -$161.85 -$142.16 -$137.22
Investing activities
Capital expenditures -$2.17 -$1.35 -$2.38 -$0.51
Investments -$129.33 -$126.89 $18.19 -$6.34
Total cash flows from investing -$131.5 -$128.24 $15.8 -$6.86
Financing activities
Dividends paid
Sale and purchase of stock $8.68 $14.96 $65.79 $95.72
Net borrowings $25.98 $73.07 $293.87 $192.16
Total cash flows from financing $32.48 $88.03 $359.67 $302.7
Effect of exchange rate $0.36 $0.57 $0.07
Change in cash and equivalents -$193.79 -$201.5 $233.39 $158.63
Fundamentals
Market cap $1.05B
Enterprise value $1.78B
Shares outstanding 205.77M
Revenue $331.41M
EBITDA N/A
EBIT N/A
Net Income -$226.54M
Revenue Q/Q 17.42%
Revenue Y/Y N/A
P/E ratio -4.61
EV/Sales 5.38
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 3.15
P/B ratio -2.29
Book/Share -2.22
Cash/Share 0.55
EPS -$1.10
ROA -43.58%
ROE 57.22%
Debt/Equity -2.13
Net debt/EBITDA N/A
Current ratio 3.31
Quick ratio 3.12